Neogen Chemicals (NEOGEN) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved with an unmodified audit opinion from statutory auditors.

• Final dividend of ₹1 per equity share recommended for FY 2025-26, subject to shareholder approval.

• Amendments to the Code for prevention of insider trading were approved.

Financial highlights

• Standalone revenue from operations for FY 2025-26 was ₹855.49 crore, up from ₹773.65 crore year-over-year.

• Standalone net profit for FY 2025-26 was ₹46.96 crore, compared to ₹48.41 crore in FY 2024-25.

• Consolidated revenue from operations for FY 2025-26 was ₹861.96 crore, up from ₹777.56 crore year-over-year.

• Consolidated net profit for FY 2025-26 was ₹28.75 crore, down from ₹34.83 crore in FY 2024-25.

• EPS (standalone) for FY 2025-26 was ₹17.81, compared to ₹18.35 in the previous year.

Outlook and guidance

• Management confirmed full recoverability of insurance claims related to the Dahej plant fire, with ongoing assessment and further receipts expected.

• The company continues to monitor regulatory changes, including new labor codes, and will adjust accounting as needed.